Dawn R. Mattoon
Chief Executive Officer bei Mercy Bioanalytics, Inc.
Profil
Dawn R.
Mattoon is currently the Chief Executive Officer & Director at Mercy Bioanalytics, Inc. Prior to her current position, she worked as the SVP-Strategic Marketing & Assay Technologies at Quanterix Corp.
from 2018 to 2022.
Before that, she served as the Vice President-Product Development at Cell Signaling Technology, Inc. from 2014 to 2018.
Dr. Mattoon holds a doctorate degree from Yale University.
Aktive Positionen von Dawn R. Mattoon
| Unternehmen | Position | Beginn |
|---|---|---|
Mercy Bioanalytics, Inc.
 Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | Chief Executive Officer | 15.02.2023 |
Ehemalige bekannte Positionen von Dawn R. Mattoon
| Unternehmen | Position | Ende |
|---|---|---|
| QUANTERIX CORPORATION | Chief Tech/Sci/R&D Officer | - |
Cell Signaling Technology, Inc.
 Cell Signaling Technology, Inc. Medical SpecialtiesHealth Technology Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA. | Corporate Officer/Principal | 01.02.2018 |
Ausbildung von Dawn R. Mattoon
| Yale University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| QUANTERIX CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. Medical SpecialtiesHealth Technology Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA. | Health Technology |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | Health Technology |
